A single month, reconciled. Every figure below is traced back to dispensing data, the Drug Tariff and your remittances.
A line that made money in October can turn. The dip in February is concession-driven, and recoverable.
Net cost versus what you were actually reimbursed, line by line, so loss-making and over-tariff items stop hiding inside the average. Click a column to sort; filter by flag.
| Item▾ | Net cost▾ | Reimbursed▾ | Margin £▾ | Flag▾ |
|---|---|---|---|---|
| Total, 16 lines shown | £42,180 | £61,200 | , |
Net margin by therapeutic class. Two classes carry the practice; two are losing money.
A ranked list of what to do, with the value at stake. None of it requires changing what you prescribe.
Wholesaler rebate running ~13% against a ~25% achievable rate. The single biggest lever, a procurement conversation, not a clinical one.
Lines bought above reimbursement during shortages. ≈ £11,100 over six months versus what the Tariff paid back.
≈ £19k a year of contribution that evaporates if specific price concessions are withdrawn. Worth watching and hedging.
A cheaper same-month source existed on several lines. Ordering discipline, not concessions, quick to fix.
Every review ships these, finished, audited and ready to act on. Open the samples below (fictional data).
A review looks back; this looks forward. Ashcombe is fictional, so the local-growth figures here are illustrative. The 2026/27 contract and QOF facts are real and apply to any English practice. Every projected figure shows its working and a range.
Ashcombe sits on the edge of a growing market town with an allocated urban extension. A real review would model your own local plan, household size and registration share; the figures below are illustrative for a fictional practice.
About 1% to 3% of an 8,400 list over five years. The larger pressure is ageing, not headcount: in an older list, demand and complexity per patient climb faster than the headcount does.
The 2026/27 contract was imposed from 1 April 2026. The Global Sum rose from £123.34 to £130.07 per weighted patient, an increase of £6.73.
Offsets to weigh: the dispensing fee per item fell for April to September 2026, with an October uplift expected but not yet published; National Living Wage rose to £12.71 an hour with employer NI at 15% and no Employment Allowance. The weighted list is not known here, so the uplift is indicative. Net effect: a modest capitation gain, not a windfall.
QOF rose to 582 points at £227.95 a point, mostly a list-size effect, with no income protection this year. For a high achiever the risk is in the changed indicators. QOF maths uses the contractor population index, about 10,295, not the registered list.
These are planning estimates based on published sources, not guarantees, and should be reviewed as figures are confirmed.
Send us a period of data and we'll show you where your dispensary is losing margin, and what it is worth to fix.